PR92786

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire=KYODO JBN/ --

As an element of Nautilus' overall reagent development and sourcing strategy,

the partnership aims to accelerate research and development, and provide

customers with access to Abcam's antibody development technology and expertise

Nautilus Biotechnology, Inc. [ https://www.nautilus.bio/ ](NASDAQ: NAUT; or

"Nautilus"), a company pioneering a single-molecule protein analysis platform

for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global

innovator in life sciences research tools, today announced a strategic

development and supply partnership.

The relationship leverages Abcam's industry-leading recombinant monoclonal

antibody development technologies and expertise to enhance Nautilus' reagent

research and development, and establishes a long-term supply relationship

between the companies. The partnership will initially focus on the

collaborative development of affinity binding reagents for use on the Nautilus

proteomic analysis system, and will expand in the near future to the

large-scale manufacture and supply of reagents for commercialization.

"We are excited to be working closely with Abcam to build reagents that we

believe will further enhance our proteomic analysis methods," said Sujal Patel,

co-founder and CEO of Nautilus Biotechnology. "They, like us, envision a future

in which proteomic data is expected to become an increasingly important

resource that has the potential to support the creation of more effective drugs

and diagnostics. Our ability to partner with a company as respected and

successful as Abcam provides a strong vote of confidence in that future, and in

the promise of the Nautilus protein analysis platform to help make it a

reality."

Abcam's scale and recombinant antibody manufacturing expertise is expected to

support Nautilus in meeting its long-term reagent supply needs from research

and development through to commercialization.

"The prospect of biomedical researchers being able to interrogate the proteome

at a more comprehensive level offers exciting possibilities for discovery and

innovation across multiple disease areas," said Alan Hirzel, CEO of Abcam. "By

combining Nautilus' protein analysis platform and Abcam's antibody discovery,

development and manufacturing expertise, we hope to better support scientists

in the development of drugs and diagnostic tools that ultimately improve

outcomes for patients."

Under the terms of the agreement, Abcam will provide Nautilus with antibodies

that are expected to add to and enhance its own library of affinity binding

reagents, highlighting the open and customizable nature of Nautilus'

technology. With simple labeling chemistry, the Nautilus platform is designed

for use with virtually any biological reagent.

About Nautilus Biotechnology, Inc.

Based in Seattle, Washington, Nautilus (Nasdaq: NAUT) is a development stage

life sciences company creating a platform technology for quantifying and

unlocking the complexity of the proteome. Nautilus' mission is to transform the

field of proteomics by democratizing access to the proteome and enabling

fundamental advancements across human health and medicine. To learn more about

Nautilus, visit www.nautilus.bio

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes

high-quality biological reagents and tools that are crucial to research, drug

discovery and diagnostics. Working across the industry, the Company supports

life scientists to achieve their mission, faster.

Abcam partners with life sciences organizations to co-create novel binders for

use in drug discovery, in vitro diagnostics and therapeutics, driven by the

Company's proprietary discovery platforms and world-leading antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the

global understanding of biology and causes of disease, which enables new

treatments and improved health. The Company's pioneering data-sharing approach

gives scientists increased confidence in their results by providing validation,

user comments and peer-reviewed citations for its 90,000 products.

With 14 sites globally, many of Abcam's over 1,600-strong team are located in

the world's leading life sciences research hubs, complementing a global network

of service and support.

To find out more, please visit www.abcam.com and corporate.abcam.com.[

https://corporate.abcam.com/ ]

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of

federal securities laws. You can identify forward-looking statements by words

such as "may," "will," "could," "can," "would," "should," "expect," "intend,"

"plan," "anticipate," "believe," "estimate," "predict," "project," "potential,"

"poised," "continue," "ongoing" or the negative of these terms or other

comparable terminology, but not all forward-looking statements will contain

these words. Forward-looking statements in this press release include, but are

not limited to, statements regarding the potential functionality and

performance of Nautilus' product platform, its potential impact on

pharmaceutical development and drug discovery, and market opportunities

available to Nautilus or Abcam generally. These statements are based on

numerous assumptions concerning the collaboration between Abcam and Nautilus

including but not limited to expectations as to the success of that

collaboration, expectations regarding the ability of that collaboration to

enhance and/or accelerate Nautilus' development efforts and to enable Nautilus

to meet long term reagent supply needs, and expectations regarding the

development of Nautilus' products and target markets, generally, and involve

substantial risks, uncertainties and other factors that may cause actual

results, levels of activity, performance or achievement to be materially

different from the information expressed or implied by these forward-looking

statements. We cannot assure you that the forward-looking statements in this

press release or the assumptions upon which they are based will prove to be

accurate. Risks and uncertainties that could materially affect the accuracy and

outcome of Nautilus' and Abcam's assumptions and its ability to achieve the

forward-looking statements set forth in this press release include (without

limitation) the following: Nautilus' product platform is not yet commercially

available and remains subject to significant scientific and technical

development, which is inherently challenging and difficult to predict,

particularly with respect to highly novel and complex products such as those

being developed by Nautilus. Even if Nautilus' development efforts are

successful, the product platform will require substantial validation of its

functionality and utility in life science research. In the course of Nautilus'

scientific and technical development and associated product validation and

commercialization, Nautilus or Abcam may experience material delays as a result

of unanticipated events.  For a more detailed description of additional risks

and uncertainties facing Nautilus and its development efforts, investors should

refer to the Registration Statement on Form S-4 and related documents filed

with the SEC. For a more detailed description of additional risks and

uncertainties facing Abcam and its development and business strategy see the

important factors discussed under the caption "Risk Factors" in Abcam's

prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange

Commission ("SEC") on 22 October 2020, which is on file with the SEC and is

available on the SEC website at www.sec.gov, as such factors may be updated

from time to time in Abcam's other filings with the SEC. The forward-looking

statements in this press release are as of the date of this press release.

Except as otherwise required by applicable law, Nautilus and Abcam disclaim any

duty to update any forward-looking statements. You should, therefore, not rely

on these forward-looking statements as representing our views as of any date

subsequent to the date of this press release.

Logo - https://mma.prnewswire.com/media/1675313/Nautilus_Abcam_logo.jpg

Joint Source: Abcam and Nautilus Biotechnology, Inc.